Pro Medicus provided earnings guidance for the second half of 2014. For the period, the company maintains its previous guidance that the second half is expected to be stronger than the reported first half results, as revenue from the VISN 23 contract commences and there is the full impact of six months of vRad revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
119.8 AUD | +2.83% | +2.98% | +24.97% |
May. 08 | CLSA Upgrades Pro Medicus to Accumulate from Reduce, Price Target is AU$125 | MT |
Apr. 02 | Pro Medicus Limited authorizes a Buyback Plan. | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.97% | 8.13B | |
+9.07% | 34.16B | |
+30.59% | 4.44B | |
-29.19% | 2.7B | |
-16.72% | 1.37B | |
-28.50% | 1.27B | |
-33.46% | 1.18B | |
+12.11% | 1B | |
-36.34% | 870M | |
-19.73% | 639M |
- Stock Market
- Equities
- PME Stock
- News Pro Medicus Limited
- Pro Medicus Provides Earnings Guidance for the Second Half of 2014